Work

Overcoming Adaptive Resistance to KRAS Inhibitors Through Vertical Pathway Targeting

Year: 2020

Type: article

Abstract: KRAS G12C inhibitors have shown promise in KRAS G12C–mutant lung cancer but intrinsic and acquired resistance are common. Cotreatment with inhibitors of the protein phosphatase SHP2 can abrogate the adaptive response of cancer cells to KRAS inhibitors resulting in greater suppression of MAPK signaling and enhanced tumor growth inhibition. See related article by Ryan et al., p. 1633

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-19-4060

Authors: Rona Yaeger, David B. Solit

Institution: Memorial Sloan Kettering Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute